Neumora Therapeutics Inc (NMRA)

Jan 2, 2025, 6:40 PM EST - 26 days ago

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

Jan 2, 2025, 3:15 PM EST - 27 days ago

Neumora's depression drug fails trial, sinking shares

Jan 2, 2025, 10:55 AM EST - 27 days ago

Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals

Jan 2, 2025, 10:27 AM EST - 27 days ago

Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals

Jan 2, 2025, 7:18 AM EST - 27 days ago

Neumora Therapeutics' depression drug fails to meet main goal of late-stage study

Jan 2, 2025, 7:00 AM EST - 27 days ago

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

Dec 24, 2024, 1:11 PM EST - 5 weeks ago

Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck

Nov 13, 2024, 11:03 AM EST - 2 months ago

This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Nov 12, 2024, 11:50 AM EST - 2 months ago

Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 2 months ago

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 7:00 AM EST - 3 months ago

Neumora Therapeutics to Participate in Upcoming Conferences in November

Aug 14, 2024, 7:00 AM EDT - 6 months ago

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

Jun 20, 2024, 7:00 AM EDT - 7 months ago

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation

May 14, 2024, 7:00 AM EDT - 9 months ago

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

May 7, 2024, 7:00 AM EDT - 9 months ago

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 15, 2024, 7:13 AM EDT - 10 months ago

Neumora's early-stage schizophrenia drug study put on hold

Apr 15, 2024, 6:30 AM EDT - 10 months ago

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

Mar 13, 2024, 7:00 AM EDT - 11 months ago

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

Mar 7, 2024, 7:00 AM EST - 11 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 8, 2024, 6:25 AM EST - 1 year ago

Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling

Jan 22, 2024, 7:00 AM EST - 1 year ago

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

Jan 2, 2024, 7:00 AM EST - 1 year ago

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 12, 2023, 7:00 AM EST - 1 year ago

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

Nov 27, 2023, 7:00 AM EST - 1 year ago

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

Nov 20, 2023, 1:27 PM EST - 1 year ago

IPO pipeline welcomes some profitable companies, raising hopes for a rebound

BIRK CART KVYO SDHC VFS WAY ZK

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 18, 2023, 7:03 PM EDT - 1 year ago

Neumora: First Novel Mechanism Of Action Drug In Major Depression In Decades

Oct 10, 2023, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

Sep 27, 2023, 8:36 AM EDT - 1 year ago

Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics

AMGN

Sep 14, 2023, 8:49 PM EDT - 1 year ago

Neumora Therapeutics Announces Pricing of Initial Public Offering

Sep 12, 2023, 4:38 PM EDT - 1 year ago

IPO Update: Neumora Therapeutics Seeks $250 Million U.S. IPO